True resistant hypertension is an independent risk factor for adverse renal and cardiovascular outcomes in patients with chronic kidney disease.
Identifies true resistant hypertension as prognostic marker in CKD; leaves open whether targeted control improves renal or CV outcomes.
Resistant hypertension (RH) is defined as blood pressure (BP) that remains above the target of less than 140/90 mmHg in the general population and 130/80 mmHg in people with diabetes mellitus or chronic kidney disease (CKD) in spite of the use of at least three full-dose antihypertensive drugs including a diuretic or as BP that reaches the target by means of four or more drugs. In CKD, RH is a common condition due to a combination of factors including sodium retention, increased activity of the renin-angiotensin system, and enhanced activity of the sympathetic nervous system. Before defining the hypertensive patient as resistant it is mandatory to exclude the so-called "pseudoresistance." This condition, which refers to the apparent failure to reach BP target in spite of an appropriate antihypertensive treatment, is mainly caused by white coat hypertension that is prevalent (30%) in CKD patients. Recently we have demonstrated that "true" RH represents an independent risk factor for renal and cardiovascular outcomes in CKD patients.
No takes yet. Share an insight, caveat, or question.
Nicola et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: